MACROGENICS, INC.

MACROGENICS, INC. specializes in the research, development, and manufacturing of advanced pharmaceutical and biologic therapeutics, with a focus on novel molecular platforms for infectious disease intervention. Their technical expertise includes the design and production of dual-affinity re-targeting molecules, a sophisticated class of biotherapeutics engineered to simultaneously bind multiple targets for enhanced viral suppression—evidenced by their work on HIV-1 suppression platforms. The company applies deep knowledge in pharmaceutical preparation manufacturing, translating complex biological concepts into scalable, GMP-compliant production processes. Key differentiators lie in their ability to bridge early-stage discovery with clinical-grade manufacturing, particularly in the development of precision-targeted biologics that address unmet medical needs in immunology and virology. The contractor has delivered critical R&D and pharmaceutical manufacturing services to the Department of Health and Human Services and the Department of Veterans Affairs. For HHS, they have supported high-impact life sciences research initiatives focused on next-generation antiviral therapeutics. With the VA, they have provided specialized pharmaceutical products under federal supply schedule contracts, indicating a proven ability to meet the operational and regulatory demands of veteran healthcare delivery systems. Their industry focus centers on NAICS 541712 for life sciences R&D and 325412 for pharmaceutical manufacturing, positioning them at the intersection of innovative biologic discovery and regulated drug production. They specialize in developing and scaling complex therapeutics beyond traditional small-molecule drugs, targeting viral pathogens and hematologic conditions with precision molecular designs. As a 2L entity headquartered in Rockville, Maryland, MACROGENICS, INC. operates within the federal biopharmaceutical ecosystem with a lean, focused structure. While no government certifications are listed, their direct engagement with HHS and VA underscores their credibility in meeting stringent federal compliance standards for therapeutic development and supply. Their geographic presence in the National Capital Region supports close collaboration with federal research and procurement entities.